Drug Trial Radar · NCT07231471
Platelet Rich Plasma for Musculoskeletal Conditions
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10,000
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Jan 1, 2035
Study completion Jan 1, 2035
Sponsor
- Lead sponsor
- University of UtahAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.
Conditions
- Osteoarthritis (OA)
- Osteoarthritis (OA) of the Knee
- Osteoarthritis (OA) of the Hip
- Osteoarthritis (OA) of the Shoulder
- Osteoarthritis Ankle
- Elbow Osteoarthritis
- Epicondylitis of the Elbow
- Plantar Fasciitis of Both Feet
- Tendinopathy
Interventions
Platelet Rich Plasma InjectionBiological
Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their blood will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.
Platelet Rich Plasma PreparationDevice
The patient's blood is collected into syringes. That blood is spun in a centrifuge at high speeds, which separates their blood into layers (red blood cells, white blood cells, and plasma). The plasma portion, which contains the platelets, is transferred to a different syringe for later injection. In some cases, the plasma is spun in the centrifuge again (a "double spin" technique) to further concentrate the platelets in the plasma. The patient's blood is not exposed to air, and it is transferred by tubing between syringes with a Luer Lock connection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visual analog score (pain)Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Utah Orthoaedic Center
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.